Three things to know:
1. CartiHeal has completed enrollment and outcome of interim analysis in an investigational device exemption study of Agili-C, an implant for the treatment of cartilage lesions in joints.
2. Bioventus will provide an additional $5 million to CartiHeal if required to complete the device exemption study.
3. Terms of the deal to acquire CartiHeal were not disclosed.
More articles on biologics:
7D Surgical radiation-free spine surgery system gets European approval
Medtronic to buy Medicrea for 22% above share price: 6 details
2 hospitals with new spine surgery programs
